GHRP-2 is a potent second-generation growth hormone releasing peptide that has undergone formal Phase II and III clinical trials for GH deficiency and cachexia. It produces higher GH pulses than ipamorelin but causes modest cortisol and prolactin elevation at doses above 200 mcg.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
GHRP-2 is a second-generation growth hormone releasing peptide and one of the most potent GHRPs studied in human clinical trials. A 6-amino-acid synthetic peptide, it stimulates significantly higher GH pulses than ipamorelin and has been tested in formal Phase II clinical trials for GH deficiency and cachexia. GHRP-2 produces a dose-dependent GH increase but also causes modest elevations in cortisol and prolactin at higher doses, which places it in the intermediate category — more powerful than ipamorelin, requiring more attention to dose management.
Mechanism of Action
GHRP-2 is a full agonist of the ghrelin receptor (GHSR-1a) and also partially antagonizes somatostatin signaling, creating a dual mechanism that amplifies GH release beyond what GHRH alone can produce. At the pituitary level, GHRP-2 binding triggers a robust GH pulse via calcium-dependent signaling pathways. In addition to GHSR-1a activity, GHRP-2 activates the CD36 receptor and has been shown to stimulate cardiomyocyte survival pathways (PI3K/Akt/mTOR), which has sparked interest in cardiac protection research. At doses above 200 mcg, it begins to stimulate ACTH and cortisol release via the hypothalamic-pituitary-adrenal (HPA) axis — a key distinction from ipamorelin. GHRP-2 also has mild appetite-stimulating effects via central ghrelin receptor activation, though less pronounced than GHRP-6.
Key Research
GHRP-2 (pralmorelin) has the most extensive clinical trial record of the GHRP class. Phase II and III trials evaluated it as a diagnostic agent for GH deficiency and for cachexia/GH insufficiency treatment. The FDA accepted NDA applications based on clinical data demonstrating reliable GH stimulation in adults and children. Research confirmed its dose-dependent GH response (peak at ~100 mcg), with cortisol and prolactin elevation documented at 200+ mcg doses. Cardiac protection studies showed GHRP-2 activates anti-apoptotic pathways in cardiomyocytes via PI3K/Akt/mTOR — independent of its GH-releasing activity.
Research doses range from 100–300 mcg per injection, typically 2–3 times daily. The 100 mcg dose produces a GH pulse comparable to the high end of natural physiological range with minimal cortisol elevation. Doses of 200–300 mcg produce supraphysiological GH pulses but carry proportionally higher cortisol and prolactin response. Like all GHRPs, GHRP-2 should be administered in a fasted state or at least 2 hours post-carbohydrate meal. It is most commonly combined with CJC-1295 (no DAC or DAC) for synergistic GH amplification. Cycles of 8–16 weeks are standard, with a 4-week off period recommended for longer-term research to prevent receptor desensitization.
Strength and Body Composition Protocol: GHRP-2 200 mcg + CJC-1295 no DAC 100 mcg twice daily (morning fasted + pre-bed) for 12 weeks. Maximum GH Protocol: GHRP-2 300 mcg + CJC-1295 DAC 2 mg twice weekly (with GHRP-2 3x daily) for 8–12 weeks. Consider adding a low-dose dopamine agonist (e.g., cabergoline) to manage prolactin if using higher doses consistently.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
The most notable side effects of GHRP-2 compared to ipamorelin are cortisol and prolactin elevation, particularly at doses above 200 mcg. Chronic cortisol elevation can impair sleep quality, immune function, and body composition — counterproductive to the goals of GH therapy. Increased appetite is reported but is less intense than with GHRP-6. Water retention, joint stiffness, and tingling in extremities are common at GH-elevating doses. Some users report a flushing sensation or warmth immediately after injection. At high doses, fatigue and mild hypoglycemia can occur. Long-term use without cycling may lead to GHSR desensitization, reducing responsiveness over time.
Storage & Handling
Store lyophilized GHRP-2 at 2–8°C for up to 18 months. Protect from light, moisture, and heat. Reconstitute with bacteriostatic water and refrigerate; use reconstituted solution within 28 days. Do not freeze reconstituted peptide. A common reconstitution for a 5 mg vial is 2.5 mL BAC water, yielding 2 mcg/µL (200 mcg per 10 units on a U-100 syringe).
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
